HomepageEVGN • NASDAQ
add
Evogene Ltd
Vorige slotkoers
$Â 1,57
Dag-range
$Â 1,45 - $Â 1,57
Jaar-range
$Â 1,20 - $Â 10,40
Beurswaarde
8,21Â mln. USD
Gem. volume
66,81K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,80Â mln. | -52,32% |
Bedrijfskosten | 8,17Â mln. | 9,83% |
Netto inkomsten | -7,63Â mln. | -91,52% |
Netto winstmarge | -424,83 | -301,69% |
Winst per aandeel | -1,31 | -63,75% |
EBITDA | -6,83Â mln. | -93,87% |
Effectief belastingtarief | -0,01% | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 19,95Â mln. | -46,40% |
Totale activa | 40,11Â mln. | -30,53% |
Totale passiva | 27,88Â mln. | 27,39% |
Totaal aandelenvermogen | 12,24 mln. | — |
Uitstaande aandelen | 6,79 mln. | — |
Koers-boekwaardeverhouding | -2,45 | — |
Rendement op activa | -45,97% | — |
Rendement op kapitaal | -110,69% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -7,63Â mln. | -91,52% |
Operationele kasstroom | -4,93Â mln. | -14,15% |
Kasstroom uit beleggingen | 2,02Â mln. | -44,68% |
Kasstroom uit financiering | 4,73Â mln. | -39,30% |
Nettomutatie in liquide middelen | 1,83Â mln. | -74,18% |
Vrije kasstroom | 1,24Â mln. | 140,67% |
Over
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Opgericht
2002
Website
Werknemers
142